Cardiol Therapeutics (CRDL) Change in Receivables (2020 - 2026)
Cardiol Therapeutics' (CRDL) quarterly Change in Receivables came in at -$10463.4 in Q1 2026, down 161.52% YoY from $17008.9 in Q1 2025, and up 19.97% on a QoQ basis from -$13074.6 in Q4 2025.
Cardiol Therapeutics (CRDL) Change in Receivables (2020 - 2026) Analysis & Trends
Cardiol Therapeutics (CRDL) has 7 years of Change in Receivables data on file, last reported at -$10463.4 in Q1 2026.
- Quarterly Change in Receivables fell 161.52% year-over-year to -$10463.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4328.9 (down 92.4% YoY) and the FY2025 annual result came in at $32010.0, up 5.51% from the prior year.
- Change in Receivables grew to -$10463.4 in Q1 2026, from -$13074.6 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $44105.3 in Q2 2024 to a low of -$41111.7 in Q4 2022.
- A 5-year average of -$440.58 and a median of $7058.9 in 2023 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 985.38% — and 2024, when it soared 524.82%.
- Tracing CRDL's Change in Receivables over 5 years: stood at -$41111.7 in 2022, then soared by 162.97% to $25888.7 in 2023, then sank by 219.69% to -$30987.0 in 2024, then surged by 57.81% to -$13074.6 in 2025, then climbed by 19.97% to -$10463.4 in 2026.
- The last three Change in Receivables figures came in at -$10463.4 (Q1 2026), -$13074.6 (Q4 2025), and $15569.6 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 91.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 66.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -445.26 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -1.70 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 126.50 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 84.30 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Cardiol Therapeutics | 215.50 Mn | 196.65 Mn | - | 4,334.66 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10,463.37 |
| Mar 31, 2026 | -10,463.37 |
| Dec 31, 2025 | -13,074.63 |
| Dec 31, 2025 | -13,074.63 |
| Sep 30, 2025 | 15,569.61 |
| Sep 30, 2025 | 15,569.61 |
| Jun 30, 2025 | 12,297.26 |
| Jun 30, 2025 | 12,297.26 |
| Mar 31, 2025 | 17,008.94 |
| Mar 31, 2025 | 17,008.94 |
| Dec 31, 2024 | -30,986.96 |
| Dec 31, 2024 | -30,986.96 |
| Sep 30, 2024 | 26,809.23 |
| Sep 30, 2024 | 26,809.23 |
| Jun 30, 2024 | 44,105.32 |
| Jun 30, 2024 | 44,105.32 |
| Mar 31, 2024 | -8,333.93 |
| Mar 31, 2024 | -8,333.93 |
| Dec 31, 2023 | 25,888.70 |
| Dec 31, 2023 | 25,888.70 |